Expanding RNAi Delivery to Muscle Tissue Through Antibody Oligonucleotide Conjugates

  • Antibody-siRNA conjugates enable muscle-selective uptake, treating myopathies with minimal off-target effects
  • Enhanced endosomal escape increases cytoplasmic siRNA release, improving dystrophin restoration in Duchenne MD
  • Modular platform allows rapid re-targeting, accelerating therapies for multiple rare muscle disorders